1/25
Looks like no tags are added yet.
group 1
antineoplastic drugs (chemo)
group 2
non-antineoplastic drugs
group 3
drugs that pose a reproductive risk to men and women who are actively trying to conceive, and women who are either pregnant or breastfeeding
hazardous drug
a drug that exhibits one or more of the following characteristics in humans or animals:
1) carcinogenicity
2) teratogenicity
3) reproductive toxicity
4) organ toxicity (at low doses)
5) genotoxicity
6) new drugs with structure/toxicity profiles similar to existing hazardous drugs
carcinogenicity
an agent that can cause cancer; tumors present in more than one species and gender of animals (can't just be rodents)
carcinogens
Ex: estrogens (endometrial cancer, cardiovascular risk); valganciclovir, various antineoplastic agents
tetratogenicity
an agent that disturbs or causes a malformation in the development of an embryo or fetus (birth defects, termination of the pregnancy); don't necessarily cause sterility
tetratogens
Ex: thalidomide; warfarin (fetal warfarin syndrome - saddle nose, retarded growth, defects of limbs, eyes, and CNS)
reproductive toxicity
an agent that damages reproductive organs and can cause sterility or birth defects
category A
FDA category in which adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and no evidence of risk in later trimesters)
category B
FDA category in which animal reproduction studies have failed to demonstrate a risk to the fetus and here are no adequate and well-controlled studies in pregnant women
category C
FDA category in which animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks
category D
FDA category in which there is postive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits my warrant use of the drug in pregnant women despite potential risks
category X
FDA category in which studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits
do not
effects noted in doses greater than the maximum recommended human dose (MRHD) _______ count as hazardous
do
effects noted in doses less than the maximum recommended human dose (MRHD) _______ count as hazardous
organ toxicity
damage to organs at low doses of the drugs: up to 10 mg/day or up to 1 mg/kg/day
genotoxicity
something that can cause DNA or chromosomal damage in vivo or in vitro
Ex: methotrexate
Hazardous drug resources
ASHP, USP 800, ISMP, NIOSH, US Environmental Protection Agency, your employer
protection
__________ against hazardous drugs: PPE, policy and procedure, training, product labeling, safety data sheets, product disposal
PPE
goal is to completely prevent exposure; wear double gloves, gown, hairnet, mask or respirator, double shoe covers; use biological safety cabinet (BSC) or compounding aseptic containment isolator (CAIC)
handling
PPE required for ________________: gown, head and hair protection, single chemo gloves, single shoe covers, respiratory protection if unpacking HDs that aren't wrapped in plastic until packing can be assessed
compounding
PPE required for __________________: gown, head and hair protection, double chemo gloves, double shoe covers, ventilated engineering controls (fume hood or BSC), eye, face, and respiratory protection if risk of spills/splashes/inhalation
labeled
ALL hazardous drugs must be __________ as hazardous with bright colors that are easily seen
yellow
___________ bins are for disposal of remnants of chemotherapy; small volumes and empty packages
black
____________ bins are for disposal of all hazardous drugs and spill kids